HST Global Announces Details of Protocol Licensing for Health Matters International

HAMPTON, Va.--()--HST Global, Inc. (OTCBB: HSTC) today announced that it has formalized the licensing details for Health Matters International.

As previously announced, HST Global Inc. (HST) has partnered with Health Matters International (HMI), a Canadian Company that has vast international knowledge in the Healthcare Industry. Through this association, HMI identified Panama and Costa Rica as potential countries for the development of HST’s Clinical Treatment Facilities which features the company’s “FIT” protocol.

HMI focuses on providing a solution to the rising cost of prescription medications and other health care related matters. They pride themselves on ensuring safe, high quality and low cost prescription medications through their Canadian and International Pharmacies. Headquartered in Calgary, Alberta with pharmacies in New Zealand, Italy, India, USA and Canada they employ a safe, high quality and low cost methodology for delivery of prescription medication.

HMI will be funding the initial licensing fee. HMI’s licensing fee will be $250,000. This license fee will permit HMI to provide the “FIT” protocol within Panama and Costa Rica. The fee incorporates training, initial products and onsite development for each respective clinical team. In addition, HMI will pay a royalty on each individual application of the “FIT” protocol administered within each clinic. The clinics will also be purchasing a regime of post-therapy medications also provided by HST under the same royalty agreement.

About HST Global, Inc.

HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that is developing and or acquiring a network of Wellness Centers worldwide that are primarily focused on the immunotherapy and alternative treatment of late stage cancer. In addition, the company intends to acquire innovative products for the treatment of late stage cancer. In this regard, the company primarily focuses on immunotherapy and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer.

HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

Contacts

HST Global, Inc.
Investor Relations
David Nesbitt, 757-766-6100
ir@hstglobal.com
www.hstglobal.com

Contacts

HST Global, Inc.
Investor Relations
David Nesbitt, 757-766-6100
ir@hstglobal.com
www.hstglobal.com